PEG-8甘油月桂酸酯 | 57107-95-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: PEG-8甘油月桂酸酯
• 中文别名: PEG-15甘油月桂酸酯
• 英文名称: 2-[2,3-Bis(2-hydroxyethoxy)propoxy]ethanol;dodecanoic acid
• 英文别名: 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;dodecanoic acid
• CAS: 57107-95-6
• 化学式: C21H44O8
• 分子量: 424.6
• InChiKey: DKWXCDCBSHDIJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.37
• 重原子数：
  29
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
  申请人：iTeos Belgium SA

  公开号：US11376255B2

  公开（公告）日：2022-07-05

  The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-α-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.

  本发明涉及可用作 A2A 腺苷受体（A2AR）抑制剂的式 (I) 硫代氨基甲酸酯衍生物 特别是，本发明涉及一种药物组合物，该组合物包含式（I）的 A2A 抑制剂和脂质载体，例如月桂酰基大环醇-32 甘油酸酯、D-α-生育酚-聚乙二醇-1000 丁二酸酯或它们的混合物。本发明的药物组合物特别适用于治疗癌症的口服剂量。本发明还涉及一种由式（I）的 A2A 受体抑制剂和抗癌剂组成的组合物。抗癌剂例如是免疫治疗剂，如检查点抑制剂。本发明还涉及一种药物组合物和包含这种组合物的部件试剂盒。此外，本发明的组合物特别适用于治疗和/或预防癌症。
• THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS
  申请人：iTeos Belgium SA

  公开号：EP3849558A1

  公开（公告）日：2021-07-21
• USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST
  申请人：iTeos Belgium SA

  公开号：EP3856181A1

  公开（公告）日：2021-08-04
• [EN] THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS<br/>[FR] DÉRIVÉS DE THIOCARBAMATE EN TANT QU'INHIBITEURS D'A2A, COMPOSITION PHARMACEUTIQUE ASSOCIÉE ET COMBINAISONS AVEC DES AGENTS ANTICANCÉREUX
  申请人：ITEOS THERAPEUTICS S A

  公开号：WO2020053263A1

  公开（公告）日：2020-03-19

  The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors (I). Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-α-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.
• [EN] USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST<br/>[FR] UTILISATION D'UN INHIBITEUR D'UN TRANSPORTEUR DE LA FAMILLE DES ENT DANS LE TRAITEMENT DU CANCER ET DE LA COMBINAISON DE CEUX-CI AVEC UN ANTAGONISTE DU RÉCEPTEUR DE L'ADÉNOSINE
  申请人：ITEOS THERAPEUTICS S A

  公开号：WO2020065036A1

  公开（公告）日：2020-04-02

  The present invention relates to the use of an inhibitor of an ENT family transporter for the treatment of cancer. The invention further relates to the combined use of such inhibitor of an ENT family transporter with an adenosine receptor antagonist, for the treatment of cancer. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination.